Numinus Wellness Inc. NUMI.TO

Company Overview

Numinus Wellness Inc. is a Canadian mental health care company focused on psychedelic-assisted therapy, behavioral health services, and related clinical support infrastructure. The company operates in the broader healthcare, mental health, and psychedelic medicine sectors, with activities spanning psychotherapy clinics, practitioner training, clinical research support, and operational infrastructure for regulated psychedelic treatments. Numinus has positioned itself as an integrated provider combining clinical care delivery with practitioner education and research-oriented capabilities tied to emerging psychedelic-assisted treatment models.

The company’s primary business lines have included psychotherapy and psychiatric services delivered through clinic networks, practitioner certification and training programs, and operational support for clinical trials and psychedelic-assisted treatment protocols. Historically, Numinus expanded through acquisitions and partnerships tied to ketamine-assisted therapy and psychedelic research infrastructure. The company was founded in 2020 and grew during a period of heightened investor and medical interest in psychedelic therapies for conditions such as depression, PTSD, anxiety, and substance use disorders. Public filings and company disclosures indicate that its strategic positioning has emphasized early participation in regulated psychedelic-assisted mental health care markets in Canada and the United States.

Business Operations

Numinus has operated through integrated mental health and wellness service offerings centered on psychotherapy clinics and psychedelic-assisted treatment support. Its operational model has included clinical care delivery, practitioner education, protocol development, and support services for research organizations. The company previously operated through business units and subsidiaries including Numinus Health, Numinus Bioscience, and acquired clinic assets such as Novamind, which expanded its presence in the U.S. behavioral health market. Revenue generation has primarily been tied to clinical services, therapy programs, practitioner training, and related healthcare activities.

The company’s operations have included both domestic Canadian activities and cross-border U.S. operations, particularly through clinic networks and mental health service centers. Numinus has also participated in research collaborations connected to psychedelic-assisted therapies involving compounds such as psilocybin and MDMA within regulated clinical frameworks. Public disclosures and market reporting indicate that the company has sought to build operational capabilities around therapist training, patient screening, treatment administration support, and clinical infrastructure intended to align with evolving regulatory pathways for psychedelic medicine.

Strategic Position & Investments

Numinus has pursued a strategy centered on becoming an integrated mental health platform capable of supporting future commercialization and adoption of psychedelic-assisted therapies. Growth initiatives have historically included acquisitions of behavioral health clinics, expansion of therapist training programs, and investment in clinical infrastructure designed to support scalable treatment delivery. The acquisition of Novamind Inc. represented one of the company’s most significant expansion initiatives, strengthening its U.S. clinic footprint and practitioner network.

The company has also maintained involvement in emerging sectors related to psychedelic medicine, including ketamine-assisted therapy and preparation for potential regulatory approval of MDMA- and psilocybin-assisted treatments. Numinus has engaged in industry partnerships and clinical ecosystem development tied to practitioner education and treatment readiness. Publicly available filings indicate strategic emphasis on integrating evidence-based psychotherapy with regulated psychedelic treatment protocols. Some long-term commercial outcomes related to broader psychedelic medicine adoption remain dependent on regulatory developments and reimbursement frameworks, which continue to evolve across jurisdictions.

Geographic Footprint

Numinus is headquartered in Vancouver, British Columbia, Canada, and has historically maintained operations across both Canada and the United States. Its clinic and service footprint expanded significantly in the U.S. through acquisitions and operational growth initiatives, particularly in behavioral health and psychotherapy services. The company has targeted major urban and healthcare markets where demand for mental health services and alternative treatment modalities has increased.

The company’s operational influence has primarily been concentrated in North America, although its practitioner training programs and participation in psychedelic medicine discussions have contributed to broader international visibility within the mental health and research communities. Public filings and investor materials indicate that the company has focused its commercial activities largely within regulated North American healthcare systems rather than broad international retail expansion.

Leadership & Governance

Numinus was founded by Payton Nyquvest, who has served as a central figure in shaping the company’s strategy around integrated psychedelic-assisted mental health care. Leadership communications and investor materials have consistently emphasized patient-centered care, evidence-based treatment models, and preparation for emerging regulatory frameworks tied to psychedelic medicine. The company’s governance structure has included executives with backgrounds in healthcare operations, finance, clinical services, and pharmaceutical or mental health sectors.

Key executives and leadership figures have included:

• Payton Nyquvest – Founder and Chief Executive Officer
• Michael Tan – Chief Financial Officer
• Reid Robison, MD – Chief Clinical Officer
• Shannon Carlin – Chief Operating Officer
• Louis Gagnon – Director and strategic advisor roles reported in company disclosures

Leadership and executive composition may change over time based on corporate filings and restructuring activities. Certain executive role changes reported across public sources may differ depending on reporting period and filing date.